1099-081X/asset/BDD_left.gif?v=1&s=c11e8078e868403f8ca4b2a7b9807faafa9d1c98)
1099-081X/asset/BDD_right.gif?v=1&s=7deb44a49db3df64c5f6356bcbf8e918ac003681)
Original Paper
Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males
Article first published online: 5 FEB 2012
DOI: 10.1002/bdd.1770
Copyright © 2012 John Wiley & Sons, Ltd.
Additional Information
How to Cite
Hakooz, N. and Salem, I. I. (2012), Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males. Biopharm. Drug Dispos., 33: 15–21. doi: 10.1002/bdd.1770
Publication History
- Issue published online: 7 MAR 2012
- Article first published online: 5 FEB 2012
- Accepted manuscript online: 23 JAN 2012 06:20AM EST
- Manuscript Accepted: 7 JAN 2012
- Manuscript Revised: 28 DEC 2011
- Manuscript Received: 1 NOV 2011
- Abstract
- Article
- References
- Cited By
Keywords:
- desloratadine;
- poor metabolizers;
- phenotype;
- Jordanians
ABSTRACT
Purpose
To study the prevalence of desloratadine slow metabolizer phenotype among a group of healthy Jordanian male volunteers.
Methods
A total of 62 healthy Jordanian male volunteers were included in this study. A single 5 mg desloratadine oral tablet was given and blood samples were taken to determine the desloratadine and 3-hydroxydesloratadine (3-OH-desloratadine) concentrations using a specific liquid chromatography-mass spectrometric method (LC/MS/MS). The determination of pharmacokinetic parameters of all the individuals was determined by using Kinetica® program version 4.1. Poor metabolizers or slow metabolizers of desloratadine were determined as individuals having a 3-OH-desloratadine to desloratadine exposure ratio lower than 10% or a desloratadine half-life ≥ 50 h.
Results
Among the 62 volunteers who participated in the study there were only two volunteers who were labeled as desloratadine slow metabolizers, giving a prevalence of 3.2%. The maximum plasma concentrations (Cmax) were similar in the extensive and slow metabolizers groups but a longer time (tmax) was needed to achieve this concentration in one of the volunteers who was a desloratadine slow metabolizer.
Conclusion
The incidence of the poor metabolizer phenotype of desloratadine in the Jordanian population studied is similar to certain ethnic groups (e.g. Asian, Caucasians and Hispanic); however, it is lower than other populations (e.g. American Indians and Black). Copyright © 2012 John Wiley & Sons, Ltd.